anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Table

Component collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 60,557
Current window 47,251-47,280
Pages 2,019
Rows per page 30
Component: Tableclear collectionreset all
18 30 60

Component

47,251-47,280 of 60,557

filter-aware
16
The slide uses color-coding to indicate capacity status (green for available, red for no capacity, blue for busy pricing, yellow for negative busy pricing).Instacart | Product Presentation Deck | 20 slides · Instacart
Conference presentation Investor relations 1 hit
04
The slide uses a grid layout to categorize transaction details into Industry Logic, Aggregate Consideration, Combination, and Shareholder Impact.Micro Focus | Mergers and Acquisitions Presentation Deck | 29 slides · Micro Focus
Conference presentation Investment bank Beat · Situation & ContextLoop · Logic Chain1 hit
34
The study design follows the CLSI EP05-A3 standard.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Evidence1 hit
36
The slide includes a disclaimer at the bottom regarding FDA clearance status.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Evidence1 hit
37
The slide references CLSI EP09-A3, a standard for method comparison and bias estimation using patient samples.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Evidence1 hit
40
The slide includes a disclaimer at the bottom regarding FDA clearance.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Evidence1 hit
41
The slide uses a table to validate performance against industry-standard benchmarks.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Evidence1 hit
44
References CLSI EP05-A3 standard.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Complication1 hit
45
The slide includes a disclaimer about FDA clearance status and definitions for (L) and (H) samples.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Complication1 hit
46
The slide outlines the clinical study parameters for a Herpes diagnostic test.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Complication1 hit
47
Includes FDA clearance references and disclaimer.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Complication1 hit
52
References CLSI EP05-A3 standard for precision performance testing.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
53
Includes FDA disclaimer and definitions for (L) and (N) cell counts.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
54
The slide uses a standard table format to define the parameters of a clinical validation study.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
57
Includes technical definitions of error metrics and regulatory disclaimers.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
61
The slide compares the assay's LoD (480 copies/mL) against the CDC Zika test LoD (930 copies/mL).Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
62
n = 3 replicates per test; FDA disclaimer present.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
63
The slide includes a disclaimer that the technology is not FDA cleared.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
64
n = 3 replicates per test; FDA disclaimer present.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
65
The slide includes a disclaimer at the bottom regarding FDA clearance status.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
66
The slide presents experimental validation data for a diagnostic assay.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
67
Includes a standard Theranos FDA disclaimer at the bottom.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
68
Includes FDA disclaimer at the bottom.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Results1 hit
73
This slide outlines technical mitigation strategies for blood sample collection issues.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Results1 hit
79
The slide uses a standard table format to define the parameters of a clinical validation study.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Conclusion1 hit
81
Passing-Bablok regression used for analysis.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Conclusion1 hit
82
This slide is from a Theranos presentation, likely used to establish the scientific rigor of their testing methodology.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Conclusion1 hit
84
Passing-Bablok regression used for analysis.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Conclusion1 hit
85
Theranos | Investor Conference Presentation Deck | 88 slidesTheranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Conclusion1 hit
86
The slide presents clinical validation data for a diagnostic assay.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Conclusion1 hit